Q301--674-23-3-035-0018 | NEW | CTX MDxHealth GPS

Special Notice

Page 3 of 3

*= Required Field

Special Notice

Page 1 of 3

Special Notice of Intent to Award a Sole Source Procurement

The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, intends to award a firm-fixed priced contract to MDxHealth for Laboratory Fee Basis Testing. MDxHealth SA has acquired Oncotype DX® GPS (Genomic Prostate Score® or GPS) test from Genomic Health, Inc., a subsidiary of Exact Sciences Corporation. The purpose of the resulting contract will be to provide a Blanket Purchase Agreement (BPA) for Laboratory Fee Basis Testing for MDxHealth Genomic Oncology Testing for the Central Texas Veterans Health Care System (CTVHCS), at 1901 Veterans Memorial Blvd, Temple, Texas 76504. Contractor is to provide healthcare resources in accordance with Public Law 104.262 and 38 U.S.C. 8153.

SCOPE OF WORK

Contractor shall provide in accordance with the specifications outlined Oncotype DX genomic oncology testing, during the period of 6/5/2023 through 6/4/2024 with four (4) one-year option renewals extending from 6/5/2024 through 6/4/2028.

Services shall include:

The performance, reporting and score of Oncotype DX analytical testing for Prostate cancers.

SPECIMEN TESTING

The Contractor and/or subcontractor shall provide the full range of clinical and anatomic pathology diagnostic testing capabilities to execute all required tests as annotated in the Scope of Work. Contractor shall make available the following test information:

Requisition form requirements

Alphabetized test name list

Test order code

Specimen collection and preservation requirements

Test method employed (indicate if testing performed in duplicate) and interpretations

Test reference intervals adjusted for age, sex, or race, when required

Test specific sensitivity, specificity, and interferences, when required

Result code

Test critical values if any

Policy for critical value notification

CPT coding

Test turnaround times (minimum and maximum times indicated); where the turnaround time is defined as the time between pick-up of specimen by the Contractor and receipt of results by a government facility.

Schedule of test performance (specific days of week indicated)

Location of test performance by test name (i.e., name of primary laboratory, name of separate branch/division of primary lab, name, and address of secondary (sub-contracted) laboratory must be cited)

This notice is not to be considered a request for quotations or proposals. A contract will not be awarded based on an offer received in response to this notice; however, all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 10 days from the publication of this notice, a contract will be issued to MDxHealth.

The anticipated statutory authority permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1 Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements.

Notice: the POC for this notice does not have a Federal Business Opportunities registration account. Do NOT respond in the Interested Vendors List . The POC does not have any visibility to the Interested Vendors List tab within the notice. Interested firms must respond directly to the POC email address listed in the notice for consideration.